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Objective: To evaluate the effectiveness of providing clinicians with regular feedback on the 
patient’s motivation for treatment in increasing treatment engagement in patients with severe 
mental illness.
Methods: Design: cluster randomized controlled trial (Dutch Trials Registry NTR2968). 
Participants: adult outpatients with a primary diagnosis of a psychotic disorder or a personality 
disorder and their clinicians, treated in 12 community mental health teams (the clusters) of 
two mental health institutions in the Netherlands. Interventions: monthly motivation feedback 
(MF) generated by clinicians additional to treatment as usual (TAU) and TAU by the commu-
nity mental health teams. Primary outcome: treatment engagement at patient level, assessed at 
12 months by clinicians. Randomization: teams were allocated to MF or TAU by a computerized 
randomization program that randomized each team to a single treatment by blocks of varying 
size. All participants within these teams received similar treatment. Clinicians and patients were 
not blind to treatment allocation at the 12-month assessment.
Results: The 294 randomized patients (148 MF, 146 TAU) and 57 clinicians (29 MF, 28 TAU) 
of 12 teams (6 MF, 6 TAU) were analyzed according to the intention-to-treat principle. No 
statistically significant differences between treatment groups on treatment engagement were 
found (adjusted mean difference =0.1, 95% confidence interval =-2.2 to 2.3, P=0.96, d=0). Pre-
planned ancillary analyses showed statistically significant interaction effects between treatment 
group and primary diagnosis on treatment motivation and quality of life (secondary outcomes), 
which were beneficial for patients with a primary diagnosis of a personality disorder but not for 
those with a psychotic disorder. There were no reports of adverse events.
Conclusion: The current findings imply that monitoring and discussing the patient’s motiva-
tion is insufficient to improve motivation and treatment engagement, and suggests that more 
elaborate interventions for severe mental illness patients are needed.
Keywords: randomized controlled trial, feedback, motivation, adherence, psychotic disorders, 
personality disorders
Introduction
Background
A common consideration in clinical practice is that evaluation of the patient’s 
 motivation may help understand how a patient may best be engaged in treatment.1–5 
Patients with severe mental illness (SMI), such as those with psychotic disorders or 
severe personality disorders, are often considered not motivated to seek treatment6 or 
fail to adhere to treatment programs.7,8 Regular assessment of motivation for engag-
ing in treatment and providing this as feedback to the clinician might be a promising 
approach to both monitor the patient’s motivation and provide a useful structure 
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in the communication about it. Such communication may 
help to improve motivation for treatment and treatment 
engagement.9 Meta-analyses have shown beneficial effects 
of employing feedback to clinicians on their patients’ men-
tal health outcomes.10–12 However, most clinician feedback 
research has focused primarily upon treatment outcomes13–16 
and was unable to determine which specific elements from 
the feedback provided the mechanism(s) of action. Motiva-
tion for treatment has been used as part of such feedback 
systems, yet to our knowledge and based on an extensive 
review,10 no previous study has investigated the effects of 
providing feedback that is exclusively based on the SMI 
patient’s motivation for treatment. This warrants the current 
investigation.
The theoretical basis of the motivation feedback (MF) 
intervention was founded on Self-determination Theory 
(SDT); a theory of motivation that defines several types of 
motivation that fall along a continuum of self-determination 
and describes how social and cultural factors can facilitate 
or undermine people’s sense of self-determination.17,18 SDT 
states that the most externally determined form of treatment 
motivation is when a patient remains in treatment because 
he feels pressured to do so.18 This external motivation could, 
for example, be present in a patient who is court-ordered into 
treatment.19 Also, relatively external yet somewhat more 
autonomous is introjected motivation, where a patient is 
driven by feelings of guilt or shame. A patient with introjected 
motivation might act to avoid disapproval or guilt or receive 
approval or praise (eg, from the mental health worker or 
important others). More autonomous motivation is present 
in a patient with identified motivation, who recognizes and 
accepts that treatment is useful for achieving personally rel-
evant goals.18 An example is a patient who finds it important 
to take medications as a way of preventing relapse. According 
to SDT, engaging in treatment for a long time requires that 
patients internalize treatment values since behaviors that are 
more autonomous (ie, more self-determined) are more likely 
to be performed again, whereas behaviors that are primarily 
driven by external motives will only be performed in the 
presence of such perceived external pressures.18,20
Objectives and hypothesis
The current study aimed at evaluating the effectiveness of 
MF intervention compared to treatment as usual (TAU) in 
outpatients with SMI treated by community mental health 
teams. It was hypothesized that SDT-based MF would lead 
to increased treatment engagement (primary outcome), and 
to a beneficial shift in the SDT motivation continuum toward 
more autonomous motivation and improved psychosocial 
functioning and quality of life (secondary outcomes) in 
outpatients with SMI.
Methods
Trial design and ethics statement
This study was a two-center cluster randomized trial com-
paring MF and TAU. Cluster randomization was chosen to 
avoid contamination bias.21 The full trial protocol is available 
elsewhere.9 Briefly, the cluster randomized controlled trial 
was designed with the primary objective of determining the 
effectiveness of MF intervention on treatment engagement 
(primary outcome) of outpatients with psychotic disorders 
and personality disorders, compared to TAU in community 
mental health care teams (the clusters). Secondary outcomes 
include treatment motivation, psychosocial functioning, and 
quality of life. The specific aspects of the broader trial design, 
including details of settings, interventions, randomization, 
and blinding, are also addressed. Discrepancies between 
the original protocol and the current report are described 
under “Methods” and “Results” sections; these included the 
handling of skewed outcomes in the statistical analyses and 
the smaller sample size due to lower than expected recruit-
ment rate.
This study was approved by the Medical Ethical Commit-
tee for Mental Health Care Institutions (MotivaTe-IT; trial 
number NTR2968, Netherlands Trial Register, http://www.
trialregister.nl/trialreg/admin/rctview.asp?TC=2968) as well 
as by the scientific committees of the Western North Brabant 
Mental Health Center and Breburg Mental Health Center, 
the specialty mental health institutions where the data were 
collected. The authors confirm that all ongoing and related 
trials for this intervention are registered. All procedures 
were conducted according to the principles expressed in the 
Declaration of Helsinki, including the obtainment of written 
informed consent by the participants. Results are presented 
in accordance with the CONSORT statement for cluster 
randomized controlled trials.22
setting and participants
This study was initiated by GGZ Westelijk Noord Brabant, 
a specialty mental health center located in a semiurban area 
in the south-west of the Netherlands. GGz Breburg, another 
specialty mental health center in the same semiurban area, 
was also approached and agreed to join the study.
Within these two centers, patients were eligible for 
participation if they had a primary diagnosis of a psychotic 
disorder or a personality disorder (as diagnosed by the 
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psychiatrist of the team using the Diagnostic and Statistical 
Manual of Mental Disorders-Text Revision [fourth edition] 
criteria and obtained from the medical record), were aged 
between 18 and 65 years, and received individual outpatient 
treatment for their mental disorder. Exclusion criteria were 
an insufficient command of the Dutch language (which was 
estimated by the clinician who was most frequently involved 
with the patient), and a documented diagnosis of dementia 
or chronic toxic encephalopathy.
Treatment teams were eligible for participation if they 
provided outpatient assertive community mental health 
care to eligible patients. At the start of the study, 12 teams 
of the two mental health centers fulfilled this criterion 
and were approached for participation. Specifically, these 
teams included a forensic psychiatric outpatient clinic, 
three specialized psychotic outpatient treatment programs 
and eight function-assertive community treatment teams 
(FACT-teams23). FACT-teams provide assertive, outreach-
ing, community-based, and supportive psychiatric services 
to individuals with SMI.23 Clinicians within the approached 
teams were eligible for participation if they were the primary 
health-care practitioner involved with the patient, meaning 
that this clinician had the most frequent contact with the 
patient. All 12 teams agreed to participate in the study and 
as such, the trial was conducted within these teams between 
May 2011 and October 2013.
interventions: TaU and MF
TaU
In the TAU group (consisting of six teams or clusters), treat-
ment was provided by multidisciplinary assertive outreaching 
community mental health teams. TAU was guided by the 
patient’s individual symptoms and needs for care and could 
include assertive outreach, medication, social and financial 
management, job counseling, crisis interventions, cognitive 
(behavioral) therapy, the strengths-based approach, and/or 
supportive structured therapy.23 Individual case management 
was offered to patients who were more stable and needed 
long-term care, but intensive assertive outreach was offered 
to patients at risk of relapse or neglect, often by several 
clinicians working with a shared caseload.23 We did not 
seek for uniformity in TAU as such diversity reflects reality. 
Clinicians in the control group continued TAU during the 
course of the study.
MF
MF was provided in addition to TAU in patients randomized 
to the MF group (consisting of six teams or clusters). Patients 
and clinicians in the MF intervention group were asked to fill 
in a Short Motivation Feedback List (SMFL) every month 
up to 12 months after baseline assessment. The SMFL con-
sists of eight statements that relate to the level and type of 
the patient’s treatment motivation, based on three types of 
motivation postulated by SDT:18,20 external, introjected, and 
identified motivation. The SMFL was shown to be reliable 
for these three types of motivation; congeneric estimates of 
reliability ranged from 0.81 to 0.93.24,25
Before commencing the study, clinicians were trained 
by the principal investigator (PI) in the principles of SDT and 
the use of MF. The training consisted of a presentation about 
the principles and concepts of SDT, exercises to learn how to 
distinguish the needs for autonomy, competence and related-
ness, and practicing MF assessments with other clinicians 
(not yet with patients) during this training, to familiarize 
themselves with the feedback and how to communicate it. 
Clinicians received three booster sessions over the course of 
the study to evaluate and discuss their progress and experi-
ences together with other colleagues who also participated 
in MF. During the course of the study, the PI received filled-
out SMFLs from the clinicians and subsequently provided 
the clinician with MF graphs via email. An example of such 
a graph can be found in our published research protocol.9 
The evaluation of the SMFL and the graph could serve as a 
starting point for conversations between the patient and the 
clinician regarding the motivation of the patient. Clinicians 
were instructed to stimulate internalization of motivation 
by supporting the patient’s basic psychological needs of 
autonomy, competence, and relatedness, in line with SDT.26 
The intention was that the conversation would revolve around 
sources of motivation behind treatment goals. Clinicians were 
free to decide for themselves how they would structure this 
conversation with the patient, such as discussing only one 
item or several, or discuss differences between patient’s and 
clinician’s vision, and they were free to decide how long this 
would take. The duration and frequency of SMFL assess-
ments were monitored by the research team. Both the number 
of face-to-face contacts between patient and clinician and the 
number of performed SMFL assessments were counted to 
evaluate how many of the possible SMFL assessments were 
actually performed.
During the course of the study, clinicians were regularly 
contacted by the PI to monitor the MF intervention and to 
discuss progress and experiences together with other col-
leagues who also participated in the MF intervention. These 
evaluation sessions took place four times over the course 
of the study. To aid clinicians in remembering to perform 
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SMFL assessments, they were given bookmarks to use in 
their paper planners, posters of the study were hung up in 
the team offices, electronic reminders were regularly placed 
in the electronic planners, the PI was regularly present in the 
team office to check up on progress, and emails were sent to 
remind the clinicians of using MF.
Outcomes
The outcomes of interest were treatment engagement 
(primary outcome) and treatment motivation, psychosocial 
functioning, and quality of life (secondary outcomes).9 
We also administered a number of other comprehensive 
instruments, including measures for baseline characteristics 
used in the current study, for which we refer to our research 
protocol.9 All instruments were administered in Dutch 
language.
Primary outcomes
Treatment engagement was measured with the Service 
Engagement Scale (SES) that was filled out by clinicians. The 
SES was developed to measure engagement with community 
mental health services.27 It comprises 14 items that assess 
availability, collaboration, help seeking, and treatment 
engagement behaviors (including medication adherence). 
The items are rated on a 4-point scale ranging from 0 (not 
at all) to 3 (most of the time). The SES has shown good psy-
chometric properties and has previously been used in studies 
with patients with psychotic disorders.27–29 The SES total 
scale score was used as the outcome measure in this study, 
where higher scores denote higher treatment engagement. 
Reliability of the total scale score in the current sample was 
considered good, as evaluated by a congeneric estimate of 
reliability of 0.91. Additionally, we included the number of 
missed appointments (no-shows), as a more objective mea-
sure of treatment engagement.9 These were obtained from 
the medical records.
For patients with a primary diagnosis of a psychotic 
disorder, the Morisky Medication Adherence Scale30 was 
used to assess patient self-reported antipsychotic medication 
adherence. The Morisky Medication Adherence Scale is a 
self-report scale that consists of eight items asking about a 
specific medication-taking behavior, such as “When you feel 
that your symptoms are under control, do you sometimes 
stop taking your medicine?”. The items can be scored “yes” 
or “no” and the total scale score theoretically ranges from 
0 to 8, with higher scores indicating better medication 
adherence. The congeneric estimate of reliability was 0.82 
in the current sample.
secondary outcomes
Motivation for engaging in treatment as postulated by SDT 
was measured with the Treatment Entry Questionnaire 
(TEQ)24,31 that was administered to both patients and 
clinicians. It contains three subscales (external, introjected, 
and identified motivation), each with six items rated on a 
scale from 1 (strongly disagree) to 7 (strongly agree), and 
subscale scores are computed by averaging the item scores 
and multiplying this by the number of items. The congeneric 
estimates of reliability for TEQ subscales were acceptable 
in the current study sample as evaluated by congeneric esti-
mates of reliability; 0.78 for identified motivation, 0.72 for 
introjected motivation, and 0.75 for external motivation.24 
Construct validity for the TEQ was supported by signifi-
cant associations with therapist-rated service engagement 
(correlations between -0.15 and 0.58 (P,0.01), depending on 
the subscale), patient- and clinician-rated therapeutic alliance 
(eg, r=0.47 and r=0.25, P,0.01, respectively with identified 
motivation) and legally mandated treatment.24 Higher scale 
scores denote higher levels of that type of motivation.
The patient’s psychosocial functioning was measured 
with the Dutch version of the Health of the Nations Outcome 
Scales (HoNOS).32 The HoNOS was administered as a 
semistructured interview with the patient, performed by 
independent research assistants (mostly graduate students in 
psychology and medicine). The researchers had no involve-
ment in the patient’s treatment. Patients were interviewed at 
the team office or at home, depending on their preference. The 
HoNOS quantifies health and social problems of the previ-
ous 2 weeks and contains 12 items that refer to behavioral 
problems, cognitive and physical impairments, symptoms, 
and social (dis) functioning. HoNOS items are scored on a 
scale from 0 (no problem) to 4 (severe problem). The total 
scale score is computed by adding the 12 items. A higher 
total score on the HoNOS denotes more severely impaired 
psychosocial functioning. The psychometric properties 
of the total scale score were shown to be acceptable and 
sensitive to change.32 Reliability of the total scale score was 
adequate in the current sample, as reflected by a congeneric 
estimate of reliability of 0.77.
The patient’s quality of life was assessed with the Man-
chester Short Assessment of Quality of Life (MANSA).33,34 
The MANSA is a self-report questionnaire that asks the 
patient how satisfied he/she is in the following life domains: 
living situation, social relationships, physical health, mental 
health, safety, financial situation, work situation, and life 
as a whole. The mean score on the 12 MANSA items was 
used as the outcome measure, of which the psychometric 
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properties are considered satisfactory.34 The congeneric 
estimate of reliability was 0.91 for the MANSA total score in 
the current sample. Higher scores denote a higher perceived 
quality of life.
sample size
The sample size was calculated on the basis of our primary 
hypothesis that MF would be more effective than TAU in 
enhancing treatment engagement, as measured with the 
SES at 12 months after baseline assessment. The difference 
between the MF group and control group for the primary 
outcome was based on a power of 0.80, an alpha of 0.05 
(two-tailed), and an effect size (standardized mean differ-
ence) of 0.40.9 The clustering of patients within clinicians 
was accounted for using the variance inflation factor formula 
f =1+ (m–1) ρ, with an estimated cluster size (m) of six 
patients per clinician and the within-cluster correlation (ρ) 
was estimated from a previous study to be around 0.07.35 
Using these parameters and including an additional correc-
tion for expected loss-to-follow-up, it was estimated that the 
required total sample size should be 350 patients.9
randomization
sequence generation
A computer-generated list of random numbers was used to 
randomly assign each team to a treatment condition, such that 
all clinicians and patients in the same team were randomized 
to a similar treatment.
Type
The randomization sequence was created using software 
from www.randomization.org with a 1:1 allocation ratio 
using random block sizes of 1, 2, and 3.
implementation
The random allocation sequence was performed by authors 
ECJ and HJD prior to approaching treatment teams, such 
that treatment teams and their members were still unknown 
and were numbered blindly before entering team numbers 
into the computer program.
Blinding
At baseline, patients were unaware (blind) as to which treat-
ment condition they had been randomized to. Clinicians had 
to be made aware of treatment condition as those random-
ized to MF needed to receive the necessary training prior to 
baseline assessments such that MF could start immediately 
thereafter. This blinding procedure is common in psychiatric 
intervention research.21 At the 12-month assessment, 
clinicians and patients were not blind to treatment condition 
while filling in questionnaires, whereas independent research 
assistants who looked up information from the medical 
record and performed interviews with patients were blind 
to treatment allocation.
Procedures
Treatment teams were approached by the PI and clinicians 
working in these teams received oral and written informa-
tion about the study and were asked for informed consent. 
Subsequently, clinicians were asked to provide their case-
load to the PI, who randomly selected ten eligible patients 
for participation (or if fewer than ten eligible patients were 
available, all the eligible patients were selected). Clinicians 
explained to the selected patients the contents and procedure 
of the study and asked for participation. To enhance the 
likelihood of participation, patients were given an incentive 
of €15 for participating. If a patient consented to participate, 
an appointment was made with the PI, sometimes accom-
panied by the clinician for the patient’s comfort and/or the 
investigator’s safety. The patient received oral and written 
information about the contents and procedures of the study 
once more before signing informed consent. Subsequently, 
patients and clinicians completed the baseline assessments. 
Independent research assistants accompanied patients during 
the assessment, such that they could help if necessary. This 
could, for example, include reading items aloud to accom-
modate patients with concentration problems and/or explain-
ing items that were not readily understood. This procedure 
took about 2 hours for most patients and about 20 minutes 
for clinicians.
After 12 months, patients and clinicians were contacted 
for the follow-up assessment. Patients who had ended 
treatment or dropped out from treatment were nonetheless 
contacted for a follow-up assessment. Clinicians were asked 
to complete their follow-up assessment for all patients who 
were enrolled at start of the study. Furthermore, it was 
assessed to what extent the MF intervention was performed 
by the clinicians.
statistical methods
Several outcomes, including the primary outcome and the 
motivation questionnaires, were not normally distributed 
at follow-up assessment and transformations were not suc-
cessful. To deal with this, difference scores were calculated 
as follow-up assessment minus baseline assessment. The dif-
ference scores showed normal distributions for all outcomes, 
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as evaluated by histograms and normal probability plots. 
Subsequently, they were used as outcomes in this study.
Differences in demographic and clinical variables at 
baseline between the intervention group and control group, 
and between participants and nonparticipants, were evaluated 
with independent samples t-tests and chi-square tests. All 
analyses were conducted using a significance level of P,0.05 
(two-sided) and unstandardized estimates of regression 
coefficients (β), 95% confidence intervals (95% CI), inter-
quartile ranges, intraclass correlation coefficients, and stan-
dardized mean differences are reported where appropriate. 
Statistical tests were performed using IBM SPSS Statistics 
21 (IBM Corporation, Armonk, NY, USA) and SAS version 
9.3 (SAS Institute Inc., Cary, NC, USA).
intention-to-treat analyses
All outcomes were analyzed with multilevel linear regres-
sion models. As stated in the study protocol,9 it was explored 
which and how many levels would be appropriate for 
inclusion in the multilevel analyses. Not all available levels 
(ie, mental health institutions, teams, clinicians, patients, and 
measurements) could simultaneously be included as random 
effects due to singularity problems. Considering the variances 
explained at each level (on average: 81% at patient-level, 8% 
at clinician-level, 1% at team-level, and 0% at mental health 
institution) and considering that the dispersion of patients 
over teams was larger than the  dispersion over clinicians 
(12–38 patients per team versus 1–10 patients per clinician), 
it was decided to include “team” as the second level in the 
analyses.
Furthermore, all analyses were performed both unadjusted 
and adjusted for baseline imbalances between treatment 
groups. In unadjusted analyses, models included treatment 
as fixed effect and clustering at team-level as a random 
effect. In adjusted analyses, models included treatment and a 
multivariate confounder score as fixed effect, and clustering 
at team-level as random effect. The multivariate confound-
ers score was calculated using a set of observed potential 
confounders to control for the observed differences in the 
distribution of baseline variables between treatment groups.36 
The multivariate confounder score included ethnicity, sex, 
educational level, primary diagnosis, addiction problems, the 
clinician’s years of clinical working experience, and the base-
line value of the respective outcome (eg, the baseline score 
on the SES was added to the confounder score in the analyses 
for SES at follow-up). Further, for all models, missing data 
on baseline variables were not imputed; only all observed 
data were used. Missing data on outcomes were considered 
missing at random. Restricted maximum likelihood was used 
as the estimation method.
additional analyses
Per protocol analyses
As stated in the study protocol,9 we wanted to investigate the 
effect of actual exposure to the intervention on outcomes. 
To this end, a per protocol analyses was performed in which a 
median split was performed on the number of SMFL assess-
ments, such that patients who performed MF less than four 
times were removed from analyses despite their randomiza-
tion to MF. The modeling approach of these per protocol 
analyses was similar to the intention-to-treat analyses.
Test of interaction effects: the role of primary diagnosis 
and age
As stated in the study protocol,9 we were also interested in 
determining whether treatment effects were dependent on 
baseline characteristics of the sample. To limit the number of 
tests (and accompanying problems of multiple testing), it was 
decided to test for differences between patients with psychotic 
disorders and patients with personality disorders and to test 
for potential differential effects of age. The two diagnostic 
groups constitute the great majority of patients treated in asser-
tive outreach teams in the Netherlands;23 but previous studies 
have largely focused on patients with psychotic disorders and 
ignored the experiences of service users with personality dis-
orders in motivational interventions and/or outcome feedback 
systems.15,37,38 Therefore, exploratory analyses were performed 
to detect whether the effects of treatment on all outcomes were 
modified by the primary diagnosis. Additionally, as previous 
studies in community mental health care for patients with SMI 
in the Netherlands have shown that treatment outcomes such 
as psychosocial functioning were dependent on patient age,39 
it was decided to explore whether the effects of treatment on 
all outcomes were modified by age. We tested these possible 
interactions (treatment group by primary diagnosis and treat-
ment group by age) for significance on all outcomes.
Results
Participant flow, recruitment, and 
numbers analyzed
The numbers of participants who were randomly assigned, 
received intended treatment, were lost to follow-up, and the 
total numbers analyzed are shown in the flowchart (Figure 1). 
Ultimately, a total of 57 clinicians and 294 eligible patients 
signed the written informed consent and completed base-
line assessments between May 2011 and September 2012. 
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7UHDWPHQWSURJUDPVWHDPVDSSURDFKHGWRSDUWLFLSDWHQ 
&OLQLFLDQVDSSURDFKHGWRSDUWLFLSDWHQ 
7HDPVDJUHHLQJWRSDUWLFLSDWHQ 
&OLQLFLDQVDJUHHLQJWRSDUWLFLSDWHQ 
3DWLHQWVDVVHVVHGIRUHOLJLELOLW\Q 
7HDPVUDQGRPL]HGQ 
&OLQLFLDQVQ 
3DWLHQWVQ 
•5HIXVHGQ 
•'HFHDVHGQ 
7HDPVFOLQLFLDQVORVWWRIROORZXSQ 3DWLHQWVORVWWRIROORZXSQ 
•8QDEOHWRFRQWDFWQ 
7HDPVFOLQLFLDQVORVWWRIROORZXSQ 
3DWLHQWVORVWWRIROORZXSQ 
•5HIXVHGQ 
•8QDEOHWRFRQWDFWQ 
3DWLHQWVDQDO\]HG
•,QWHQWLRQWRWUHDW Q H[FOXGHG 
•3HUSURWRFRO Q H[FOXGHG 
([FOXGHGSDWLHQWVQ 
•1RWPHHWLQJLQFOXVLRQFULWHULDQ 
•:DVQRORQJHULQFDVHORDGRI SDUWLFLSDWLQJFOLQLFLDQQ 
•'HFHDVHGEHIRUHEDVHOLQHQ 
(OLJLEOHSDWLHQWVQRWLQVWXG\Q 
•'HFOLQHGWRSDUWLFLSDWHQ 
•&RXOGQRWEHFRQWDFWHGGHVSLWH UHSHDWHGDWWHPSWVQ 
3DWLHQWVDQDO\]HG
•,QWHQWLRQWRWUHDW Q H[FOXGHG 
•3HUSURWRFRO Q SDWLHQWVUHPRYHG
&OLQLFLDQVQ 
3DWLHQWVQ 
0RWLYDWLRQIHHGEDFNLQWHUYHQWLRQJURXS
7HDPVQ 
0HGLDQQXPEHURISDWLHQWV
,45 ±PLQ PD[ 
,45 ±PLQ PD[ 
•'LGQRWUHFHLYHLQWHUYHQWLRQQ 
♦&OLQLFLDQIRUJRW 
♦1RWLQFRQWDFWZLWKVHUYLFHV 
♦&OLQLFLDQIHOWLWZDVLQDSSURSULDWH 
•5HFHLYHGDOORFDWHGLQWHUYHQWLRQQ 
•3HUFOLQLFLDQ 
•3HUWHDP 
7UHDWPHQWDVXVXDOJURXS
&OLQLFLDQVQ 
3DWLHQWVQ 
7HDPVQ 
0HGLDQQXPEHURISDWLHQWV
,45 ±PLQ PD[ 
,45 ±PLQ PD[ 
•5HFHLYHGDOORFDWHGLQWHUYHQWLRQQ 
•3HUFOLQLFLDQ 
•3HUWHDP 
Figure 1 Flow diagram of MotivaTe-iT.
Abbreviations: iQr, interquartile range; min, observed minimum; max, observed maximum.
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The recruitment process was slower and more difficult than 
expected, and despite extending the inclusion period by 4 
months, the inclusion of patients did not reach the estimated 
necessary 350 patients.
In total, 58% of the eligible patients (294 out of 507) and 
80% of clinicians (57 out of 71) actually agreed to participate. 
Of the 155 patients who declined participation in the trial, 
53 patients (34%) did not feel capable of filling in the ques-
tionnaires. For example, they found it too long or too much 
(n=18) or they felt they were too ill or incapable at the moment 
(n=12). Another 51 patients (33%) were not interested or did 
not feel the need to participate, and 16 patients (10%) said 
they did not want to have anything to do with mental health 
affiliations. Another 18 patients (12%) did not see the use 
of scientific research in general, nine patients (6%) started 
out with the baseline assessment but quit before completing, 
and eight patients (5%) did not give a reason for declining 
participation. Additionally, 58 patients could not be contacted 
despite several attempts. Patients who declined participation 
were significantly more often those with a primary diagnosis 
of a psychotic disorder and less often those with a personality 
disorder (χ2 [1, N=470] =8.70, P,0.01).
At 12 months, 253 patients (86%) were reassessed. 
Numbers lost to follow-up were not significantly different 
between intervention groups. The group that was lost to 
follow-up was significantly more often of non-Dutch ethnic-
ity (48% versus 26%, P,0.01) and more often had a legal 
mandate for treatment (18% versus 7%, P=0.03) compared 
to completers. Clinicians completed their follow-up assess-
ments for 278 patients (95%).
Baseline characteristics
The baseline sociodemographic and clinical characteristics 
of participating patients are shown in Table 1. At baseline, 
several patient characteristics were unequally distributed 
over the two treatment groups (Table 1). Clinicians in the MF 
group had an average of 5 more years of working experience 
(20 versus 15 years, P,0.01).
adherence to MF intervention
On average, four assessments with the SMFL were done per 
patient (standard deviation =3, observed range =0–11), rep-
resenting 45% of the possible SMFL assessments that could 
have been performed considering the frequency of contacts 
Table 1 Baseline characteristics of participating patients
Motivation feedback (N=148) Treatment as usual (N=146)
age, years, mean (sD) 45.47 (10.4)* 42.50 (10.0)*
Male sex, n (%) 98 (66.2) 81 (55.5)
Dutch ethnicitya, n (%) 116 (78.4)** 92 (63.0)**
education level, n (%)
No education/elementary 57 (38.5) 51 (34.9)
secondary school 57 (38.5) 67 (45.9)
$Upper high school 32 (21.6) 27 (18.5)
living situation, n (%)
alone 88 (59.5)** 59 (40.4)**
With partner and/or children 49 (33.1)* 70 (47.9)*
Mental health center facility 10 (6.8) 16 (11.0)
homeless 1 (0.7) 1 (0.7)
Primary diagnosis, n (%)
Psychotic disorder 104 (70.2) 95 (65.1)
Personality disorder 44 (29.7) 51 (34.9)
comorbid substance use problemsb, n (% yes) 42 (28.4) 32 (21.9)
Prescribed medication, n (%)
classical antipsychotics 37 (25.0) 26 (17.8)
atypical antipsychotics 63 (42.6) 67 (45.9)
combination of typical and atypical 12 (8.1) 15 (10.3)
Benzodiazepines 42 (28.4) 39 (26.7)
antidepressants 40 (27.0) 53 (36.3)
Age of first contact with mental health, mean (SD) 27.16 (10.34) 24.95 (10.24)
One or more previous hospitalizations, n (% yes) 113 (76.4) 114 (78.1)
legal mandate, n (% yes) 11 (7.4) 13 (8.9)
Notes: aThe definition of Dutch ethnicity was based on the definition by the Dutch Bureau of Statistics.57 bSubstance abuse problem was defined as having a DSM-IV diagnosis 
of substance abuse and/or dependence in the medical record. *P,0.05, **P,0.01.
Abbreviations: SD, standard deviation; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition.
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with patients. Clinicians reported that the median time of 
discussing the SMFL with the patient was 10 minutes (inter-
quartile ranges =5–15 minutes). Eighteen out of 148 patients 
(12%) never completed any SMFL assessments (reasons are 
shown in Figure 1). All clinicians in MF had at least one 
patient who was actively involved in MF, so there was no 
clinician who never performed SMFL assessments.
intention-to-treat analyses of outcomes
Table 2 shows pre- and postintervention medians and the 
results of intention-to-treat analyses for all outcome measures, 
both unadjusted and adjusted for the multivariate confounder 
score. In the following, we will describe the results of the 
adjusted analyses, which are similar to the results of unad-
justed analyses in terms of interpretation.
It can be seen from Table 2 that we found no statistically 
significant differences between the MF and TAU groups in 
terms of treatment engagement, neither as measured with the 
SES nor as measured by the number of no-shows. Neither did 
we find significant differences between treatment groups in 
patients with primarily psychotic disorders, regarding their 
self-reported medication adherence. Regarding motivation 
for treatment, no statistically significant treatment effects 
were found for patient-reported motivation, but clinicians 
reported that MF reduced patients’ introjected motives for 
engaging in treatment more than TAU (adjusted mean dif-
ference [AMD] =-4.5, 95% CI =-6.4 to -2.6, P,0.001). 
Neither any of the other motivation scales nor the patient’s 
psychosocial functioning and quality of life were significantly 
differently affected between the two treatment groups.
ancillary analyses
Per protocol analyses
The results of the per protocol analyses were comparable to the 
findings of the intention-to-treat analyses. That is, no statisti-
cally significant differences between the MF and TAU groups 
were found in terms of treatment engagement (as measured 
with the SES and number of no-shows) and patient-reported 
motivation. The findings on clinician-reported introjected 
motivation were confirmed such that clinicians reported a 
significantly higher reduction of introjected motivation in MF 
than in TAU (AMD =-4.9, 95% CI =-7.4 to -2.4, P,0.001). 
Additionally, we found an effect on clinician-reported external 
motivation such that clinicians reported less external motiva-
tion in MF compared to TAU (AMD =-3.2, 95% CI=-6.2 
to -0.3, P,0.03). No statistically significant differences 
between the MF and TAU groups were found for psychosocial 
functioning and quality of life.
Test of interaction effects: the role of primary 
diagnosis and age
Results of the interaction analyses showed no statistically 
significant differential treatment effect of the primary diag-
nosis on changes in treatment engagement as assessed by 
the SES (P=0.50) and the number of no-shows (P=0.09). No 
differential effects on patient-reported treatment motivation 
were found, but the interaction effect between treatment 
group and primary diagnosis was significant for clinician-
reported identified motivation (β=-3.77, 95% CI =-7.12 
to -0.42, P=0.03) and clinician-reported introjected motiva-
tion (β=-5.07, 95% CI =-8.67 to -1.59, P,0.01) (Figure 2 
for estimates of accompanying main effects). As depicted in 
Figure 2, clinicians reported opposing treatment effects for 
identified motivation in the two diagnostic groups, such that 
they reported increased identified motivation in patients with 
a primary diagnosis of a personality disorder and decreased 
identified motivation in patients with a primary diagnosis 
of a psychotic disorder. For introjected motivation, it was 
found that clinicians reported a higher increase in introjected 
motivation in TAU than in MF for both diagnostic groups, 
but it was more pronounced for patients with a psychotic 
disorder.
Further, the interaction effect between treatment group 
and primary diagnosis was significant for patient-reported 
quality of life (β=-0.62, 95% CI =-1.08 to -0.15, P=0.01), 
such that patients reported opposing treatment effects 
depending on their diagnostic group; those with a primary 
diagnosis of a personality disorder reported a signifi-
cantly higher quality of life in MF whereas patients with a 
primary diagnosis of a psychotic disorder reported lower 
quality of life in MF (Figure 2). No significant interaction 
effects between treatment group and primary diagnosis were 
found on the patient’s psychosocial functioning. Finally, none 
of the interaction effects between treatment group and age 
reached statistical significance, suggesting that the effects of 
treatment were not dependent on patient age.
harms
No adverse or unintended effects of the MF intervention or 
of TAU were reported.
Discussion
Main findings
There were no significant differences between MF and TAU 
regarding clinician-rated treatment engagement and the number 
of no-shows (primary outcome), and there were no differences 
regarding the patient’s psychosocial functioning and quality of 
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life (secondary outcomes). Regarding the secondary outcome 
motivation for engaging in treatment, we found no statistically 
significant differences between the MF and TAU groups on 
patient-reported motivation. Clinicians, however, did report 
that MF reduced introjected motives for engaging in treatment 
more than TAU, albeit that the effect size was small.
interpretation and possible mechanisms
Apparently, SMI patients felt that talking about their motiva-
tion with their clinician did not change their motivation nor 
treatment engagement, and clinicians felt that MF did not 
improve their patient’s treatment engagement. These find-
ings thus question whether monitoring and discussing the 
current motivational profile of the patient is necessary and 
sufficient to cause beneficial change in treatment motivation 
and behaviors such as treatment engagement.
Interestingly, the results show that clinicians did feel 
that MF changed their patient’s motivation as they reported 
lower introjected motivation and, when four or more MF 
sessions were performed, also lower external motivation. 
This suggests that clinicians noticed a reduction in rela-
tively external motivation for engaging in treatment in their 
patients in response to MF, signifying that their perception 
of the patient’s motivation has changed in response to the 
intervention. We have previously found that introjected 
motivation for treatment was especially difficult for clinicians 
to estimate in the current patient sample,40 and it is therefore 
reasonable to assume that the repeated conversations with 
patients regarding their motives has led to a change in the 
clinician’s perception of the motivation such that it became 
more closely aligned with the patient’s perspective. As such, 
the intervention may have enhanced the clinician’s ability to 
estimate the patient’s perspective on motivation.
The finding regarding the change in clinician’s ratings 
of the patient’s motivation raises the question of whether 
this is a beneficial outcome. If one takes a process-oriented 
perspective,41 improving the ability of clinicians to estimate 
their patient’s motivation or – if one were to assume that 
clinicians actually perceived a reduction in external motives – 
improving the overall quality of motivation for engaging 
in treatment can be considered beneficial in itself. On the 
other hand, if one takes an outcome-oriented perspective and 
observes that changes in motivation do not result in beneficial 
changes in treatment engagement or functional outcomes, the 
clinical relevance is ambiguous.
Furthermore, the interaction analyses of treatment with 
primary diagnosis suggest that clinicians felt the MF interven-
tion had opposing effects depending on the primary diagnosis. 
Figure 2 Statistically significant moderation effects of primary diagnosis on treatment effects (intention-to-treat analyses).
Notes: results predict change values based on a two-level multiple regression model that included treatment, primary diagnosis, treatment by primary diagnosis (interaction 
effect) and a multivariate confounder score which included patient sex, ethnicity, educational level, comorbid addiction problems, years of working experience of the clinician, 
and the baseline value of the outcome. Treatment was coded as “0” (treatment as usual) and “1” (motivation feedback); primary diagnosis was coded as “0” (personality 
disorder) and “1” (psychotic disorder). aModel: intercept (β=-2.72, df =11, P=0.07), treatment (β=1.90, df =246, P=0.19), primary diagnosis (β=2.03, df =246, P=0.08), 
treatment by primary diagnosis (β=-3.77, df =246, P=0.03), adjusted for the multivariate confounder score (β=2.00, df =246, P=0.41). bModel: intercept (β=-5.86, df =11, 
P,0.01), treatment (β=-1.0, df =246, P=0.52), primary diagnosis (β=3.11, df =246, P=0.01), treatment by primary diagnosis (β=-5.07, df =246, P,0.01), adjusted for the 
multivariate confounder score (β=7.86, df =246, P,0.01). cModel: intercept (β=0.12, df =11, P=0.56), treatment (β=0.45, df =221, P=0.04), primary diagnosis (β=0.17, df =221, 
P=0.32), treatment by primary diagnosis (β=-0.62, df =221, P,0.01), adjusted for the multivariate confounder score (β=–0.27, df =221, P=0.42).
Abbreviations: TeQ, treatment entry questionnaire; MaNsa, Manchester short assessment for quality of life.
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It should be noted that, considering the theoretically possible 
changes on the TEQ scales (-36 to 36), the observed changes 
are small and the clinical relevance and implications are not 
straightforward. Nevertheless, impaired cognitive functioning 
in patients with psychotic disorders,42,43 including problems 
with synthetic metacognition44,45 (which involves integrating 
and bringing together several perceptions into complex ideas 
about the self and others45), may explain why the interaction 
analyses showed that MF was less effective for patients with 
psychotic disorders. Offering an intervention that requires 
patients to repeatedly reflect on internal motivational states 
while these patients may suffer such (meta) cognitive impair-
ments may have been experienced as overdemanding or even 
frustrating, even more so for patients who had a relatively high 
level of motivation at the start of the study. Alternatively, the 
“additional” personal attention that clinicians in MF give to 
their patients, as reflected by an explicit interest in the nature 
of their motivation, may be experienced as positive for those 
with primarily a personality disorder, whereas this may be 
experienced more neutral or even negative by patients with 
primarily a psychotic disorder.
comparison to other studies
Although the rationale of our study was plausible as dem-
onstrated in several studies,10,37,46 this was the first study to 
test a feedback intervention that was explicitly based on 
motivation for engaging in treatment and the first study to test 
it in a real-life heterogeneous SMI patient population. Our 
results are not consistent with results from other feedback 
studies.37,46,47 For example, a study by Raes et al46 found that 
providing feedback to substance abuse patients about their 
personal resources and readiness to change (using a motiva-
tional questionnaire based on the Transtheoretical Model48,49) 
resulted in more patients attending eight sessions of treatment 
compared to a control group who did not receive such feed-
back. Other feedback studies, performed in non-SMI patient 
populations, have shown that the use of clinical support tools 
based on therapeutic alliance, social network support, and 
motivation alongside outcome feedback systems are more 
effective at improving treatment retention and outcomes 
than outcome feedback alone.47,50 It appears that successful 
outcome monitoring systems include additional support and 
services that are necessary alongside MF to cause changes in 
clinical outcomes and that solely monitoring and discussing 
motivation is an insufficient cause for such changes.
generalizability
The estimated sample size was not reached which may have 
compromised the current results, although we feel that it is 
reasonable to assume that the statistical inferences would 
not have been different from a somewhat larger sample size. 
The current patient sample already showed relatively high 
levels of identified motivation, treatment engagement, and 
psychosocial functioning and low levels of no-shows to begin 
with (considering the range of scores). Further, the reasons 
that nonparticipants gave for declining participation in the 
trial, including feeling too ill or incapable, and the finding 
that nonparticipants were more likely to be patients with a 
psychotic disorder, suggest that the most severely ill patients 
did not participate. This may reflect that the current study 
was not successful at recruiting SMI patients with substan-
tial problems in their motivation for engaging in treatment, 
treatment engagement, and psychosocial functioning. Such 
ceiling effects and selection bias may explain why MF was 
not able to improve outcomes, and this suggests that the 
findings of the current study may not be generalizable to the 
general SMI outpatient population but are limited to patients 
who are already relatively well engaged in treatment and 
function at a relatively high level.
strengths and limitations of the study
This study had several strengths including the implementa-
tion of this study in everyday practice of the community 
mental health teams, representative TAU, independent raters, 
multiple methods for assessing motivation, intention-to-treat 
analysis, and the feasibility and low costs of the intervention. 
Finally, the number of participating patients (N=294) and 
the follow-up rate for patients (86%) was high considering 
the patient population. Despite its strengths, this study may 
be viewed as a “negative trial”, and common causes for nega-
tive trials include failures of concept, design/methodology, 
and/or logistics. We will address each of these issues in the 
following sections.
concept and rationale
Numerous studies suggest that evaluation of the patient’s 
motivation may help understand how a patient may best 
be engaged in treatment,1–5 while other studies have found 
that clinicians have difficulties in estimating their patient’s 
motivation for treatment,40 suggesting that the plausibility 
of the rationale for the current study was high. However, 
it should be noted that in the Netherlands, the accessibility 
and quality of mental health care for patients with SMI are 
currently at a relatively high level.51 TAU was provided by 
multidisciplinary treatment teams that provided tailored 
care guided by the patient’s individual symptoms and needs 
for care and could include assertive outreach, medication, 
social and financial management, job counseling, crisis 
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interventions, and psychotherapy. Such care may have 
been sufficiently effective in engaging patients with SMI, 
especially highly motivated patients who were more likely 
to participate in this study, such that MF did not prove to 
be superior to TAU because the contrast between TAU and 
MF was (too) small.
Design and methodology
Although this current study was well designed,9 in hindsight 
we may conclude that the expected effect size was too high 
and that the timing of our outcome evaluation might have 
been suboptimal. A meta-analysis on the effects of feedback 
in mental health care showed that outcome feedback had 
beneficial effects if outcomes were measured within 9 weeks 
after initial assessment (d=0.10, 95% CI =0.01–0.19), but 
these effects did not persist after 3 months.10 Another meta-
analyses on continuous feedback in outpatient psychotherapy 
found similar results.52 As our study measured outcomes 
after 12 months, potential short-term beneficial changes of 
the MF intervention will have gone unnoticed and may have 
worn off by the end of follow-up. An additional assessment 
moment within the first 3 months of our study could have 
been informative in this respect, but due to practical and 
financial limitations this was not feasible.
Another methodological issue is that clinicians and 
patients were not blinded for treatment allocation, and this 
may have influenced the information that they gave on the 
outcome questionnaires (ie, information bias). Although 
this is a common design in mental health research21 and 
because blinding was not feasible, this might have biased 
the results toward no differences between the MF and TAU 
treatment groups or toward counterproductive effects of the 
MF intervention if clinicians generally did not expect the 
intervention to work or felt that the MF intervention was less/
not appropriate for patients with psychoses.
Further, although we performed evaluation sessions with 
clinicians about MF alongside the trial, we have limited 
insight into what happened during MF sessions as these were 
neither recorded nor supervised. The exact communication 
processes within the sessions and whether or not they were 
autonomy supportive remain unclear, but such processes 
might explain why the MF intervention was not successful. 
Despite the training and evaluation sessions for clinicians in 
MF, we may have failed in providing the professionals with 
the necessary competencies and tools to be able to address 
different types of motivation for engaging in treatment, and 
how to provide support for the needs of autonomy, compe-
tence, and relatedness in patients with SMI. More attention 
for the implementation process, including the influence of 
contextual factors as well as a minimum intensity of the feed-
back intervention, may be needed to reach favorable effects. 
Encouragement of both clinicians and patients to actively 
involve with MF is already difficult when facing patients with 
highly prevalent cognitive impairments, communication dif-
ficulties, and comorbidities, let alone in a health-care context 
faced with reorganizations, and as such this requires a unique 
set of competencies from both researchers and clinicians to 
ensure sufficient implementation.
The heterogeneity of this study sample is considered both 
a strength and a limitation. Our sample largely represents a 
broad population of outpatients with diagnoses of psychotic 
and personality disorders with a variety of comorbid psychi-
atric disorders, which strengthens the generalizability of the 
study and enhances the probability of adoption in clinical 
practice. However, MF may have different effects in differ-
ent subgroups of patients, which could only be addressed in 
an exploratory manner in the current study.
Measuring treatment engagement and motivation for 
engaging in treatment is complex, and gold standards are 
lacking.3,53 A strength of the current study is that we had both 
patient and clinician reports of motivation and two methods 
to assess treatment engagement. Other objective measures for 
treatment engagement and medication compliance, such as 
pill counts, electronic methods, prescription monitoring, or 
urine assay tests, were not available. Future studies may use 
such objective measures, although all have their own strengths 
and limitations.53 To our knowledge, this was the first study 
to use the TEQ in a population of patients with SMI. The 
reliability and validity of the TEQ in the current sample were 
shown to be acceptable,24 but should be improved upon and 
should be investigated more extensively to further determine 
the construct validity and sensitivity to change.
logistics
Logistic issues that have likely negatively impacted this 
study include the difficulties in recruiting the intended 
number of patients – especially the recruitment of patients 
with low levels of motivation and low levels of treatment 
engagement – and organizational changes in mental health 
care during the course of the study, including changes in 
the no-show policy and costs of mental health care for 
SMI patients. Further, there were large variations between 
teams and clinicians in the number and duration of SMFL 
assessments, reflecting the pragmatic nature of the trial. Our 
findings may reflect that too few MF sessions were actually 
utilized (ie, 45% on average) or that the way MF was used 
in the sessions was not able to beneficially affect motivation 
and treatment engagement. Frequently, clinicians admitted 
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that they regularly forgot to do SMFL assessments despite 
efforts from the research team to help them remember, and 
some reported that they were burdening the patient with “yet 
another list to fill out”. Such comments seem reflective of a 
controlling health-care context, where external demands and 
contingencies pressure people to behave in particular ways.54 
If this was the case, this is likely to have been a counterpro-
ductive mechanism in the MF intervention.26
implications for theory and practice
Theoretically, MF was expected to lead to a higher level 
of autonomous motivation which would in turn lead to a 
higher level of treatment engagement. The question remains 
if this hypothesis can be retained, but the negative results 
should not be taken as evidence against SDT, as the MF 
intervention may not have been able to successfully affect 
SDT constructs such as patient autonomy. The motivational 
constructs may still be able to predict treatment engagement 
in both conditions, and this should be addressed in subsequent 
investigations. Future studies should address which contex-
tual factors influence the implementation and interpretation 
of (motivation) feedback interventions, as these contextual 
factors can impact the motivational constructs that the inter-
vention is trying to affect.55,56
Regarding implications for clinical practice, our study 
provided no evidence for the effectiveness of MF in outpa-
tients with SMI, and this discourages the implementation 
of the SDT-based MF intervention into community mental 
health care for such patients. Nevertheless, although this 
study did not show beneficial effects of MF in SMI outpa-
tients, it contributes to the evidence base for optimal clinical 
decision-making and is relevant to prevent an overestimation 
of the benefits of feedback interventions. The findings imply 
that monitoring and discussing the patient’s motivation is 
insufficient to improve motivation and treatment engagement 
in outpatients with SMI. It appears that successful outcome 
monitoring systems include additional support and services 
alongside MF, and this allows for beneficial changes in 
clinical outcomes. In the future, there may be a place for 
SDT-based MF as a communication tool for the clinician to 
explore the patient’s perspective, after which other tailored 
interventions and services may be applied to improve patient 
motivation, treatment engagement, and, most importantly, 
symptomatic and functional outcomes.
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